draft banner

Team


M. Ryan Collins, CEO

Mr. Collins is one of the co-founders of Edenbridge Pharmaceuticals and currently serves as CEO. Mr. Collins was previously the Vice-President of Finance for DAVA Pharmaceuticals. Prior to joining DAVA, Mr. Collins served as the Assistant Controller for Anda, Inc., the distribution division of Andrx Pharmaceuticals, and also previously served as a valuation consultant for Arthur Andersen LLP. Mr. Collins holds a Master's degree in Business Administration from the University of Florida.


Patrick Chu, President

Mr. Chu is one of the co-founders of Edenbridge Pharmaceuticals and currently serves as President. Mr. Chu was previously the Director of Business Development and Associate General Counsel for DAVA Pharmaceuticals. Prior to joining DAVA, Mr. Chu worked at Wyeth and was also previously an associate at the law firm of Skadden Arps. Mr. Chu holds a law degree from Harvard Law School.


Stephen Richardson, Chief Scientific Officer

Mr. Richardson is responsible for all product development, regulatory, manufacturing and operations at Edenbridge Pharmaceuticals. Mr. Richardson has over 30 years of experience in the pharmaceutical industry. Prior to joining Edenbridge Mr. Richardson was the Chief Scientific Officer at Teligent Inc. and also previously served as a Principal Consultant at Lachman Consultants and VP of Scientific & Regulatory Affairs at JHP Pharmaceuticals. Mr. Richardson has also held senior management roles at Stiefel Laboratories and Mayne Pharma. Mr. Richardson holds a B.S. in Chemistry and Microbiology from the University of South Australia and an MBA from Adelaide University in Australia.


Victor Borelli, Senior Vice President, Sales & Marketing

Mr. Borelli has over 25 years of leadership experience in sales & marketing, well established customer relationships and a deep understanding of the generic pharmaceutical marketplace. Prior to joining Edenbridge, Mr. Borelli held the role of Vice President of Sales at Dr. Reddy's Laboratories and led that organization to become a top 10 supplier in the generic industry. Mr. Borelli holds a B.S. degree from Northeastern University.


Marc Padre, Chief Finance Officer

Mr. Padre has held finance positions in large multi-national publicly traded companies as well as small privately held pharmaceutical companies. Prior to joining Edenbridge, Mr. Padre served as Vice President, Corporate Controller for Vertice Pharmaceuticals and prior to that Mr. Padre served as the US Controller for Bausch Health Companies during a period of seventeen stock acquisitions and growth in market capital from $2B to $80B. Mr. Padre also served as an adjunct professor in accounting and information systems at The College of New Jersey. Mr. Padre earned Summa Cum Laude honors while earning a B.S. degree in Accounting from Arizona State University and was formerly licensed as a CPA in California.


Venkatesh Naini, Ph.D., Senior Vice President, Scientific Affairs

Dr. Naini is responsible for all internal product development, technical transfers and regulatory submissions at Edenbridge Pharmaceuticals. Dr. Naini has over 22 years of experience in generic pharmaceutical development and product launches. Prior to joining Edenbridge, Dr. Naini worked at several leading pharmaceutical companies including Barr, Teva, Sandoz and Aurobindo. Dr. Naini received his Ph.D. in pharmaceutics from Virginia Commonwealth University.


Daniel G. Worley Jr., PharmD, Esq., Vice President, Business Development & Associate General Counsel

Dr. Worley is a patent attorney and registered pharmacist who is responsible for all business development and legal operations at Edenbridge Pharmaceuticals. Prior to joining Edenbridge, Dr. Worley was an associate at Haug Partners LLP (f/k/a Frommer Lawrence & Haug LLP) where he specialized in patent and FDA regulatory law. Dr. Worley holds a PharmD, magna cum laude, from Rutgers University and a JD, cum laude, from Seton Hall University.


Debashis Das, Ph.D., Vice President, Analytical R&D

Dr. Das is responsible for managing the analytical laboratory at Edenbridge Pharmaceuticals and providing analytical support to formulation development, manufacturing, regulatory filings and quality control for all Edenbridge products. Prior to joining Edenbridge, Dr. Das held similar roles at Endo and Par Pharmaceuticals. Dr. Das possesses over 20 years of experience in providing analytical support to development of IND, NDA, and ANDA drug products. Dr. Das obtained his Ph.D. degree in Chemistry from Northern Illinois University.


Jason Nowack, Vice President, Quality Assurance

Mr. Nowack is responsible for all internal quality systems, oversight of external quality activities and DSCSA compliance for Edenbridge Pharmaceuticals. Mr. Nowack has over 21 years of experience in the pharmaceutical industry with 15 years in quality assurance. Prior to joining Edenbridge, Mr. Nowack was most recently the site quality head for Aprecia Pharmaceuticals. Mr. Nowack holds a B.S. degree in biotechnology from Rutgers University.